A Review on the Paper Entitled: "The Cost-Utility Analysis of PET-Scan in the Diagnosis and Treatment of Non-Small Cell Lung Carcinoma in Iran

被引：1
|
作者：
Alipour, Vahid [1 ]
Bakhsh, Ahmad Fayaz [1 ]
机构：
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Management & Econ, Tehran, Iran
来源：
IRANIAN JOURNAL OF RADIOLOGY | 2014年 / 11卷 / 04期
关键词：
Analysis; PET Scan; Carcinoma; Iran;
D O I：
10.5812/iranjradiol.18738
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PET/CT/MRI FOR DIAGNOSIS AND STAGING OF NON-SMALL CELL LUNG CANCER
    Ichikawa, Yasuko
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S25 - S26
  • [42] The role of FDG-PET in the management of non-small cell lung carcinoma
    Shon, IH
    Maisey, MN
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2004, 33 (02) : 166 - 174
  • [43] A REVIEW OF COST-EFFECTIVENESS STUDIES OF PEMBROLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Qiao, N.
    Insinga, R.
    Burke, T.
    Lopes, G.
    VALUE IN HEALTH, 2020, 23 : S41 - S42
  • [44] SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF GEFITINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN CHINA
    Hu, C.
    Huang, L.
    Zhao, D.
    Xu, L.
    VALUE IN HEALTH, 2015, 18 (07) : A459 - A459
  • [45] ERLOTINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CARCINOMA (NSCLC) - A CZECH RETROSPECTIVE ANALYSIS
    Pesek, M.
    Zatloukai, P.
    Skrickova, J.
    Kolek, V.
    Koubkova, L.
    Salajka, F.
    Sixtova, D.
    Zemanova, M.
    Roubec, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 122 - 122
  • [46] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [47] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    European Surgery, 2006, 38 (1) : 45 - 53
  • [48] Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
    Thongprasert, Sumitra
    Tinmanee, Sirana
    Permsuwan, Unchalee
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 53 - 61
  • [49] A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer
    Goulart, Bernardo
    Ramsey, Scott
    VALUE IN HEALTH, 2011, 14 (06) : 836 - 845
  • [50] COST-UTILITY OF CHEMOTHERAPY AND BEST SUPPORTIVE CARE IN NON-SMALL-CELL LUNG-CANCER
    KENNEDY, W
    REINHARZ, D
    TESSIER, G
    CONTANDRIOPOULOS, AP
    TRABUT, I
    CHAMPAGNE, F
    AYOUB, J
    PHARMACOECONOMICS, 1995, 8 (04) : 316 - 323
12345